Australia markets closed

Cullinan Therapeutics, Inc. (CGEM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.38+1.13 (+5.90%)
As of 09:46AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close19.25
Open19.27
Bid19.92 x 100
Ask24.88 x 200
Day's range19.27 - 20.38
52-week range7.64 - 20.62
Volume93,134
Avg. volume572,861
Market cap877.677M
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-3.69
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.00
  • GlobeNewswire

    Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

    CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619

  • GlobeNewswire

    Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

    CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity Corporate name change to Cullinan Therapeutics reflects strategic expansion into autoimmune diseases Cullinan Therapeutics to host a virtual investor event taking place on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) --

  • GlobeNewswire

    Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

    Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced